Interim report
Page 1
Ref . No .: WOCK / SEC / SE / 2026-27 / 030 BSE Limited Corporate Relations Department PJ Towers Dalal Street Mumbai - 400 001 Scrip Code : 532300 Dear Sir / Madam , Subject : Outcome of the Board Meeting " WOCKHARDT WINS 10th August , 2026 National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra ( E ) Mumbai - 400 051 NSE Symbol : WOCKPHARMA Pursuant to Regulation 30 of Securities and Exchange Board of India ( Listing Obligations and Disclosure Requirements ) Regulations , 2015 ( ' Listing Regulations ' ) ; and in continuation to our letter bearing reference no : WOCK / SEC / SE / 2026-27 / 027 dated 4th August , 2026 , we wish to inform you that the Board of Directors of the Company , at its meeting held today i.e. 10 th August , 2026 , inter - alia , has approved the Un - Audited Financial Results ( Standalone & Consolidated ) for the quarter ended 30th June , 2026 ; Pursuant to Regulations 30 and 33 read with Schedule III of the Listing Regulations , we enclose herewith the Un - Audited Financial Results ( Standalone & Consolidated ) for the quarter ended 30th June , 2026 along with the Limited Review Report issued by MSKC & Associates , LLP , Statutory Auditors of the Company on the same ( enclosed as Annexure I ) The meeting of the Board of Directors commenced at 1:10 p.m. and concluded at 3:05 p.m. Kindly take the same on record . Thanking you , For Wockhardt Limited Rashmi Mamtura Company Secretary Encl : as above WOCKHARDT LIMITED • Global Headquarters : Wockhardt Towers , Bandra Kurla Complex , Mumbai - 400051 , India ⚫T : 91-22-26534444 Regd . Office : D - 4 MIDC , Chikalthana , Chhatrapati Sambhajinagar - 431006 , India ⚫T : 91-240-6694444 F : 91-240-2489219 www.wockhardt.com ⚫ CIN : L24230MH1999PLC120720
Page 2
MSKC & Associates LLP Chartered Accountants /;o tity ’ .io- ' J _ 602, Floor 6, Raheja Titanium Western Express Highway, Geetanjali Railway Colony Ram Nagar, Goregaon (E) Mumbai 400063, INDIA Independent Auditor’s Review Report on standalone unaudited financial results of Wockhardt Limited for the quarter ended June 30, 2026 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. To The Board of Directors of Wockhardt Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results of Wockhardt Limited (hereinafter referred to as ‘the Company’) for the quarter ended June 30, 2026 (‘the Statement’) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘the Regulations’). 2. This Statement, which is the responsibility of the Company’s Management and has been approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder (‘Ind AS 34’) and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of I he Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For M S K C 6 Associates LLP Chartered Accountants ICAI Firm Registration Number: 001595S/S000168 ]2)i ^ Bhavik L.Shah Partner Membership No,: 122071 UDIN: 261220710LXIBA4826 Place: Mumbai ■ Date: August 10, 2026 Registered Office: 10u' Floor, Level 13th, Module 4, 21/22, Olympia Cyberspace, Alandur Road, Arulaiyammanpet, Guindy, Chennai 600032, Tamil Nadu, India Id: 44 6131 0200 | LLPIN: ACK-7004 Ahmcdabad | Bengaluru | Chennai | Giirugram | Hyderabad | Kolkata | Pune
Page 3
— WOCKHARDT LIMITED Registered Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhaji Nagar - 431 006 Global Headquarters: Wockhardt Towers, Bandra ICurla Complex, Bandra (East), Mumbai 400 051 C1N:L24230MH1999PLC 120720 Tel: 91 22 2653 4444 ; Fax: 91 22 2652 3905; e-mail id : investorrelations@wockhardt.com; Website: www.wockhardt.com STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED .It N I C 3 1 ) . 2 1 1 2 6 (Rs in Crore except per share data) PARTICULARS 3 MONTHS 3 MONTHS 3 MONTHS YEAR ENDED ENDED ENDED ENDED 30/06/2026 31/03/2026 30/06/2025 31/03/2026 (Refer notes below) Unaudited Audited Unaudited Audited (Refer note 2) 1 Income (a) Revenue from operations 561 516 413 1,739 (h) Other income 33 55 25 137 Total income 594 571 438 1,876 2 Expenses (a) Cost of materials consumed 106 79 74 309 (b) Purchase of stock-in-trade 57 40 39 198 (c) Changes in inventories of finished goods, stock-in-trade and work-in-progress 0.08 1 (0.05) (92) (d) Employee benefits expense 85 79 68 313 (e) Finance costs 4J 41 41 176 (f) Depreciation and amortisation expense 41 43 46 186 (g) Other expenses 155 156 101 494 Total expenses 487 439 369 1,584 3 Profit before exceptional items and tax (1-2) 107 132 69 292 4 Exceptional items- credit - 35 25 5 Profit before tax (3 ± 4) 107 167 69 317 6 Tax expense Current tax Deferred tax - * - - 7 Net Profit after tax (5 ± 6) 107 167 69 317 8 Other Comprehensive Income: i) Items that will not be reclassified to Profit or Loss - credit/(charge) (consisting of re-measurement of net defined benefit liability) 0 08 1 (0.23) 0.08 il) Income tax relating to items that will not be reclassified to Profit or Loss - - - - iii) Other Comprehensive Income (net of tax) (8i ± 8ii) 0.08 1 (0.23) 0.08 9 Total Comprehensive Income (7 ± 8(111)) 107 168 69 317 10 Paid-up equity share capital (face value of Rs 5/- each) 81 81 81 81 " Other Equity excluding Revaluation Reserves as per balance sheet 3,003 12 Earnings per share (face value of Rs. 5/- each) (*not annualised) (a) Basic (Rs ) 6 62* 10.29* 4.25* 19.54 (b) Diluted (R s) 6.61* 10.28* 4.25* 19.52
Page 4
Notes to Standalone results 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 10, 2026 The results have been subjected to limited review by the Statutory Auditors of the Company. 2) Figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures of the full financial year and the reviewed published figures upto the third quarter of the financial year 2025-26 3) The Company is exclusively into Pharmaceutical business segment.
Page 5
MSKC St Associates LLP Chartered Accountants 602, Floor 6, Raheja Titanium Western Express Highway, Geetanjali Railway Colony Ram Nagar, Goregaon (E) Mumbai 400063, INDIA Independent Auditor’s Review Report on consolidated unaudited financial results of Wockhardt Limited for the quarter ended June 30, 2026 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Wockhardt Limited 1. We have reviewed the accompanying statement of consolidated unaudited financial results of Wockhardt Limited (hereinafter referred to as ‘the Company’ or ‘the Holding Company’), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the ‘Group’) for the quarter ended June 30, 2026 (‘the Statement’) attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘the Regulations’). 2. This Statement, which is the responsibility of the Holding Company’s Management and approved by the Holding Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’ prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder (‘Ind AS 34’) and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’ issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable. 4. This Statement includes the results of the Holding Company and the following entities: Sr. No Name of the Entity Relationship with the Holding Company 1 Wockhardt UK Holdings Limited Wholly Owned Subsidiary 2 CP Pharmaceuticals Limited Step-Down Subsidiary 3 v CP Pharma (Schweiz) AG Step-Down Subsidiary 4 Wallis Group Limited Step-Down Subsidiary 5 The Wallis Laboratory Limited Step-Down Subsidiary Wockhardt Farmaceutica Do Brasil Ltda Step-Down Subsidiary ;istered Office: 10L | 1 Floor,,_ Level 13lh, Module 4, 21 /22, Olympia Cyberspace, Alandur Road, Arulaiyammanpet, Guindy, Chennai 600032, Tamil Nadu, India Tel: +91 44 6131 0200 | LLPIN: ACK-7004 Ahmedabad | Bengaluru | Chennai | Gurugram | Hyderabad | Kolkata | Pune
Page 6
MR** MSKC fit Associates LLP Chartered Accountants 7 Wallis Licensing Limited Step-Down Subsidiary 8 Wockhardt Infrastructure Development Limited Wholly Owned Subsidiary 9 ZEtZ Services GmbH Step-Down Subsidiary 10 Wuckhanll Europe Limited Wholly Owned Subsidiary 11 Wockhardt Nigeria Limited Step-Down Subsidiary 12 Wockhardt UK Limited Step-Down Subsidiary 13 Wockpharma Ireland Limited Step-Down Subsidiaiy 14 Pinewood Laboratories Limited Step-Down Subsidiary 15 Pinewood Healthcare Limited Step-Down Subsidiary 16 Wockhardt Holding Corp. Step-Down Subsidiary 17 MGP Inc. Step-Down Subsidiary 18 Wnckhardt Farmaceutica SA DE CV Step-Down Subsidiary 19 Wockhardt Services SA DE CV Step-Down Subsidiary 20 Wockhardt Bio AG Subsidiary 21 Wockhardt Bio (R) LLC Step-Down Subsidiary 22 Wockhardt Bio Pty Limited Step-Down Subsidiary 23 Wockhardt Medicines Limited Wholly Owned Subsidiary 24 Wockhardt Bioscience Limited (Formerly, Wockhardt Bionova Limited) Wholly Owned Subsidiary 25 Wockhardt Antibiotics (Ireland) Limited Step-Down Subsidiary 26 Wockhardt Suisse AG Step-Down Subsidiary 27 Wockhardt Suisse USA Holding Corporation Step-Down Subsidiary 28 Wockhardt Suisse USA LLC Step-Down Subsidiary 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with Llie recognition and measurement principles laid down In Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be lisclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it ins any material misstatement. jstered Office: 10"' Floor, Level 13"', Module 4 , 21/22, Olympia Cyberspace, Alandur Road, Arulaiyammanpet, Guindy, Chennai 600032, Tamil Nadu, India Tel: +91 44 6131 0200 | LLPIN: ACK-7004 Ahmedabad I Bengaluru I Chennai I Gurugram I Hyderabad I Kolkata I Mumbai I Pune
Page 7
MSKC & Associates LLP Chartered Accountants 6. We did not review the interim financial information of 5 subsidiaries included in the Statement, whose interim financial information (before Consolidation Adjustments) reflects total revenues of Rs. 777 crores, total net loss after tax of Rs. 2 crores and total comprehensive loss of Rs. 2 crores, for the quarter ended June 30, 2026. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditors. 7. The Statement includes the interim financial information of 18 subsidiaries which have not been reviewed by their auditors, whose interim financial information (before Consolidation Adjustments) reflects total revenue of Rs. 46 crores, total net profit after tax of Rs. 10 crores and total comprehensive income of Rs. 10 crores for the quarter ended June 30, 2026. These interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group. Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial result certified by the management. For M S K C Et Associates LLP Chartered Accountants ICAI Firm Registration Number: 001595S/S000168 J Bhavik L. Shah Partner Membership No.: 122071 UDIN: 26122071SCLAZ09534 Place: Mumbai Date: August 10, 2026 Registered Office: 10"' Floor, Level 13"', Module 4, 21/22, Olympia Cyberspace, Alandur Road, Arulaiyammanpet, Guindy, Chennai 600032, Tamil Nadu, India Tel: +91 44 6131 0200 | LLPIN: ACK-7004 Ahmedabad I Bengaluru I Chennai I Gurugram I Hyderabad I Kolkata I Mumbai I Pune
Page 8
WOCKHARDT LIMITED Registered Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhaji Nagar - 431 006 Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051 CIN: L24230MH1999PLC120720 Tel: 91 22 2653 4444; Fax: 91 22 2652 3905; e-mail id: investorrelations@wockhardt.com, Website: www.wockhardt.com (Rs. In Crore except per share data) STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 PARTICULARS 3 MONTHS 3 MONTHS 3 MONTHS YEAR ENDED ENDED ENDED ENDED 30/06/2026 31/03/2026 30/06/2025 31/03/2026 (Refer Notes Below) Unaudited Audited (Refer note 4) Unaudited Audited 1 Income (a) Revenue from operations 929 965 738 3,373 (b) Other income 31 45 20 111 Total income 960 1,010 758 3,484 2 Expenses (a) Cost of materials consumed 233 177 168 674 (b) Purchase of stock-in-trade 109 156 140 586 (c) Changes in inventories of finished goods, Stock-in-Trade and work-in-progress (22) (15) (44) (128) (d) Employee benefits expense 203 187 171 725 (e) Finance costs 52 50 48 213 (f) Depreciation and amortisation expense 55 53 56 227 (g) Exchange fluctuation loss, net (4) (29) 29 (22) (h) Other expenses 218 264 202 886 Total expenses 844 843 770 3,161 3 Profit /(Loss) before exceptional items and tax (1-2) 116 167 (12) 323 4 Exceptional items- charge (Note 4) - 22 (97) (85) 5 Profit /(Loss) after exceptional items and before tax (3 ± 4) 116 189 (109) 238 6 Tax expense: Current tax - charge 7 5 4 18 Deferred tax - charge/ (credit) - (Net) 2 20 (5) 21 7 Net Profit /(Loss) after tax (5 ± 6) 107 164 (108) 199 Attributable to : Equity shareholders of the Company 106 166 (90) 213 Non - Controlling Interest 1 (2) (18) (14) 8 Other Comprehensive Income (a) Items that will not be reclassified to Profit or Loss - (charge)/ credit (consisting of re-measurement of net defined benefit (liability) / asset) 0.08 71 (0.23) 70 (b) Income tax relating to items that will not be reclassified to Profit or Loss - credit/(charge) - * - - (c) Items that will be reclassified to Profit or Loss - (charge)/ credit (Consisting of Exchange differences on translating the financial statements of foreign operations) 14 79 148 349 (d) Other Comprehensive Income (net of tax) (a ± b + c) 14 150 148 419 9 Total Comprehensive Income (7 ± 8 (d» 121 314 40 618 Other Comprehensive Income attributable to : Equity shareholders of the Company 10 121 139 368 Non - Controlling Interest 4 29 9 51 14 150 148 419 Total Comprehensive Income attributable to : Equity shareholders of the Company 116 287 49 581 Non - Controlling Interest 5 27 (9) 37 121 314 40 618 10 Paid-up equity share capital (face value of Rs. 5/- each) 81 81 81 81 11 Other Equity excluding Revaluation Reserves as per Balance Sheet 4,859 12 Earnings per equity share (face value of Rs. 5/- each) (*not annualised) (a) Basic (Rs.) 6.55* 10.23* (5.53)* 13.12 (b) Diluted (Rs.) 6.55* 10.22* (5.53)* 13.10
Page 9
Notes To Consolidated Results:- The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 10, 2026. The results have ' been subjected to limited review by the Statutory Auditors of the Company. The Consolidated Results relate to Wockhardt Limited ('the Company' or 'the Holding Company') and its Subsidiaries (together constitute 'the Group') and are prepared by applying Ind AS 110 - "Consolidated Financial Statements". 3) Key Financials on Standalone basis: (Rs. In Crore) PARTICULARS 3 MONTHS ENDED 30/06/2026 3 MONTHS ENDED 31/03/2026 3 MONTHS ENDED 30/06/2025 YEAR ENDED 31/03/2026 Unaudited Audited (Refer note 4) Unaudited Audited Total Income 594 571 438 1,876 Profit (Loss) before tax 107 167 69 317 Profit (Loss) aftertax 107 167 69 317 Note: The unaudited standalone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and aie available un the Stuck Exchanges websites (www.nselndia.cuni and www.bseindia.cum) and also on the Company's website www.wockhardt.com. Figures for the quarter ended March 31, 2026 is the balancing figure between the audited figures of the full financial year and the reviewed figures upto the third quarter of financial year 2025-26. 5) The Group is exclusively into Pharmaceutical business segment. 6) For List of Subsidiaries as on June 30, 2026 please refer Annexure.
Page 10
sw itim iB tia u ia s ** uSta£aui<£' : T O M i n a w a M M M M B f t a IS ■■JifciC WOCKHARDT LIMITED Registered Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhaji Nagar - 431 006 Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051 List of Subsidiaries as on June 30, 2026 1 Wockhardt UK Holdings Limited 2 CP Pharmaceuticals Limited 3 CP Pharma (Schweiz) AG 4 Wallis Group Limited 5 The Wallis Laboratory Limited 6 Wockhardt Farmaceutica Do Brasil Ltda 7 Wallis Licensing Limited 8 Wockhardt Infrastructure Development Limited 9 Z & Z Services GmbH 10 Wockhardt Europe Limited 11 Wockhardt Nigeria Limited 12 Wockhardt UK Limited 13 Wockpharma Ireland Limited 14 Pinewood Laboratories Limited 15 Pinewood Healthcare Limited 16 Wockhardt Holding Corp. 17 MGP Inc. 18 Wockhardt Farmaceutica SA DE CV 19 Wockhardt Services SA DE CV 20 Wockhardt Bio AG 21 Wockhardt Bio (R) LLC 22 Wockhardt Bio Pty Limited 23 Wockhardt Medicines Limited 24 Wockhardt Bioscience Limited (Formerly, Wockhardt Bionova Limited) 25 Wockhardt Antibiotics (Ireland) Limited 26 Wockhardt Suisse AG 27 Wockhardt Suisse USA Holding Corporation 28 Wockhardt Suisse USA LLC